Skip to Content
Morningstar

Novavax Inc NVAX Stock Quote

Morningstar Rating
| Rating as of

Morningstar‘s Stock Analysis NVAX

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics NVAX

More

Company Profile NVAX

Business Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Contact
21 Firstfield Road
Gaithersburg, MD, 20878
T +1 240 268-2000
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Speculative Growth
Employees 1,541

Related News NVAX

Stock Strategist Industry Reports

Will Vaccine Manufacturers' Windfalls Continue Beyond 2022?

We think the COVID-19 treatment market will have more longevity.
Karen Andersen
ETF Specialist

What's in a Meme ETF?

A non-clickbait look into a few clickbait tickers.
Lan Anh Tran
Stock Strategist Industry Reports

COVID-19 Vaccine Efficacy Solid Even as Delta Extends Pandemic

Hopes for eradication fade, further highlighting the benefits of vaccination and boosters.
Karen Andersen
Fund Spy

Top Fund Managers Largely Avoided the Market’s Biggest Winners

Outside of vaccine-makers, few owned the fastest risers since the start of 2020.
Jack Shannon
Stock Strategist Industry Reports

U.S. Herd Immunity Could Be Coming by End of June

Limited vaccine supply in other countries could make global immunity tougher to achieve, though.
Karen Andersen
Stock Analyst Update

J&J Releases COVID-19 Vaccine Data

The data doesn't significantly alter our valuation or U.S. herd immunity forecast.
Karen Andersen
Stock Strategist Industry Reports

COVID-19 Sales Have No Major Impact on Drug and Vaccine Manufacturers We Cover

However, the biopharma industry's ability to adapt and innovate to treat disease reinforces our moat ratings.
Karen Andersen
Stock Strategist Industry Reports

COVID-19 Vaccine Distribution and Herd Immunity to End Pandemic

Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.
Karen Andersen
Stock Strategist Industry Reports

We Still Expect a Strong U.S. Economic Recovery

Neither the U.S. election outcome nor the coronavirus third wave will derail it.
Preston Caldwell
Investing Specialists

Karen Andersen: The Race for a COVID-19 Vaccine

The Morningstar healthcare strategist discusses the latest on COVID-19, including virus forecasts and vaccine updates from the leading biotech and pharma companies.
Christine Benz
Stock Strategist Industry Reports

A Coronavirus Vaccine, or Three, Could Be Available by Year-End

We expect multiple approved vaccines by early 2021 with wide vaccine distribution in developed markets by mid-2021.
Karen Andersen
Stock Strategist Industry Reports

Timeline Accelerates for COVID-19 Drug Development

Three new vaccines for coronavirus look poised for emergency use authorization in the U.S. this fall.
Karen Andersen